CTEV vs HIMS

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 3. 7% for Claritev Corporation (CTEV). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 69. 5x trailing P/E, making it the more compelling value choice. Analysts rate Claritev Corporation (CTEV) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +219. 5%, compared to +0. 8% for Claritev Corporation (CTEV). Over 10 years, the gap is even starker: HIMS returned +261. 9% versus CTEV's +0. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Claritev Corporation (CTEV) is the lower-risk stock at 2.

26β versus Hims & Hers Health, Inc. 's 2. 53β — meaning HIMS is approximately 12% more volatile than CTEV relative to the S&P 500.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus 3. 7% for Claritev Corporation (CTEV). On earnings-per-share growth, the picture is similar: Claritev Corporation grew EPS 83. 0% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -29. 4% for Claritev Corporation — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTEV leads at 4. 7% versus 4. 5% for HIMS. At the gross margin level — before operating expenses — HIMS leads at 73. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hims & Hers Health, Inc.

(HIMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+261. 9% 10Y return). Claritev Corporation (CTEV) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HIMS: +261. 9%, CTEV: +0. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CTEV is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.